ATyr Current Deferred Revenue from 2010 to 2026
| ATYR Stock | 0.89 0.04 4.30% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 0.9 | Current Value 0.86 | Quarterly Volatility 105.5 K |
Check ATyr Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ATyr Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 567.6 K or Gross Profit of 283.8 K, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or PTB Ratio of 3.63. ATyr financial statements analysis is a perfect complement when working with ATyr Pharma Valuation or Volatility modules.
ATyr | Current Deferred Revenue | Build AI portfolio with ATyr Stock |
Evaluating ATyr Pharma's Current Deferred Revenue across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into aTyr Pharma's fundamental strength.
Latest ATyr Pharma's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of aTyr Pharma over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. ATyr Pharma's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ATyr Pharma's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
ATyr Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 112,295 | |
| Geometric Mean | 1,228 | |
| Coefficient Of Variation | 93.95 | |
| Mean Deviation | 92,477 | |
| Median | 130,000 | |
| Standard Deviation | 105,504 | |
| Sample Variance | 11.1B | |
| Range | 255K | |
| R-Value | (0.84) | |
| Mean Square Error | 3.5B | |
| R-Squared | 0.71 | |
| Significance | 0.000023 | |
| Slope | (17,586) | |
| Total Sum of Squares | 178.1B |
ATyr Current Deferred Revenue History
About ATyr Pharma Financial Statements
ATyr Pharma shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although ATyr Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in ATyr Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on ATyr Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 0.90 | 0.86 |
Pair Trading with ATyr Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ATyr Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ATyr Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against ATyr Stock
| 0.63 | RAC | Race Oncology | PairCorr |
| 0.44 | VCEL | Vericel Corp Ord | PairCorr |
| 0.42 | OSE | OSE Pharma SA | PairCorr |
| 0.37 | VCYT | Veracyte | PairCorr |
| 0.35 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to ATyr Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ATyr Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ATyr Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling aTyr Pharma to buy it.
The correlation of ATyr Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ATyr Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if aTyr Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ATyr Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ATyr Stock Analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.